Ensemble Therapeutics Corporation is a privately held pharmaceutical and biotechnology company in Cambridge, Massachusetts. Founded in 2004 by Harvard chemist David R. Liu, the company develops and is attempting to bring to market synthetic macrocycle drugs, that is, compounds with a characteristic macrocyclic ring structure, under the trademark Ensemblins. If successful, Ensemblins would be a new class of drugs between small molecules and biologics. An orally active antagonist to Interleukin 17 has been demonstrated in animal models.